by Wendy Diller
The year 2002 would seem to have been good for manufacturers of point-of-care cardiac diagnostic markers. Significant research papers and updates to professional guidelines linked several biochemical cardiac markers ever...
More than 10 years after it was introduced on a broad scale in non-glucose applications, point-of-care testing (POCT) has found a place in carefully selected niches in hospitals. It's still not part of mainstream care, however. Data indicating the importance of getting rapid test results on cardiac markers, notably troponins and BNP, is tempting POCT in vitro diagnostics manufacturers to forge closer relationships with non-lab clinicians, even as they cater to their core, but resistant, laboratory customer base. Manufacturers are going to have to make their devices smaller, easier to use, cheaper, and better connected to data management systems if they want to lower the central labs' resistance to POCT.
by Wendy Diller
The year 2002 would seem to have been good for manufacturers of point-of-care cardiac diagnostic markers. Significant research papers and updates to professional guidelines linked several biochemical cardiac markers ever...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.